Multiple Sclerosis Drugs Market to Reach USD 39.7 Billion by 2036, Driven by Advanced Therapies and Rising Global Disease Prevalence | Latest Report TMR

Multiple Sclerosis Drugs Market Outlook 2036

The global multiple sclerosis drugs market was valued at USD 22.3 Billion in 2025 and is projected to reach USD 39.7 Billion by the end of 2036, expanding at a CAGR of 5.4% from 2026 to 2036. Market growth is driven by the rising prevalence of multiple sclerosis worldwide, advancements in disease-modifying therapies, increasing adoption of oral and high-efficacy treatments, and growing demand for personalized long-term disease management.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1130

Market Size & Highlights

• The multiple sclerosis drugs market reached USD 22.3 Billion in 2025.
• The market is projected to reach USD 39.7 Billion by 2036.
• The industry is anticipated to expand at a CAGR of 5.4% from 2026 to 2036.
• North America dominated the market in 2025, accounting for 39.7% of total revenue.
• By route of administration, the parenteral segment held the largest market share of 56.3% in 2025.
• Growing demand for disease-modifying therapies and earlier treatment initiation continues to support market expansion.

Market Overview

Multiple sclerosis (MS) is a chronic neurological disease that affects the central nervous system, potentially causing inflammation, damage to the protective myelin sheath, and progressive neurological disability. Treatment typically involves disease-modifying therapies (DMTs), which help reduce relapses and disease activity, alongside medications that manage specific symptoms.

The multiple sclerosis drugs market includes injectable, oral, and infusion-based treatments designed for different disease types and patient needs. Growing awareness, improved diagnostic capabilities, and greater access to specialist neurological care are contributing to increased treatment uptake.

Analysis of Key Players in Multiple Sclerosis Drugs Market

The global multiple sclerosis drugs market comprises leading pharmaceutical companies and biotechnology developers competing through product innovation, clinical research, strategic partnerships, and portfolio expansion.

Key companies operating in the market include:

• Biogen Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck KGaA
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• AbbVie Inc.

Major manufacturers focus on developing high-efficacy therapies, improving existing formulations, and expanding treatment options for relapsing and progressive forms of MS. Companies are also exploring biosimilars and generic alternatives to improve affordability and broaden patient access.

Key Developments in Multiple Sclerosis Drugs Market

• January 2026: ScinoPharm Taiwan received U.S. FDA approval for a generic glatiramer acetate injection for relapsing multiple sclerosis, expanding treatment alternatives in the complex generic medicines segment.

• December 2025: Sandoz introduced TYRUKO in the U.S. as a biosimilar to natalizumab, expanding access to an established treatment option for multiple sclerosis.

• December 2025: Lupin received tentative U.S. FDA approval for generic siponimod tablets for relapsing forms of multiple sclerosis. Commercial launch remains subject to applicable patent and regulatory requirements.

• November 2025: Zydus Lifesciences received U.S. FDA approval to market a generic version of Vumerity, an oral therapy used for relapsing multiple sclerosis, supporting the expansion of alternative treatment options.

Analysts' Viewpoint on the Global Multiple Sclerosis Drugs Market

Industry analysts expect the multiple sclerosis drugs market to maintain steady growth as healthcare systems emphasize early diagnosis, effective disease control, and long-term neurological care.

Rising disease prevalence and improved diagnostic capabilities are expanding the population requiring treatment. Disease-modifying therapies remain central to market development because they can reduce relapse frequency and disease activity, with treatment selection depending on disease characteristics, safety considerations, and individual patient needs.

Oral medications are attracting demand because of their convenience and ease of administration. At the same time, parenteral therapies, including monoclonal antibodies, remain important for patients requiring high-efficacy treatment and specialist supervision.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html

Key Player Strategies

💊 Development of High-Efficacy Therapies
Investing in treatments that reduce disease activity and support long-term disease management.
🧬 Biologics and Monoclonal Antibody Innovation
Improving treatment effectiveness, dosing schedules, and patient outcomes.
📈 Expansion of Oral Treatment Portfolios
Developing convenient therapies that support adherence to long-term treatment regimens.
🏥 Biosimilar and Generic Expansion
Increasing treatment alternatives and addressing affordability challenges.
🔬 Research into Progressive MS
Exploring new therapeutic approaches, neuroprotection, and potential drug repurposing opportunities.

Challenges

• High costs of branded disease-modifying therapies
• Reimbursement restrictions and pricing pressure
• Potential adverse effects and treatment-monitoring requirements
• Limited effective treatment options for certain progressive disease forms
• Complex clinical trials and lengthy drug-development timelines
• Competition from biosimilars, generics, and alternative therapies

Opportunities

⚕️ Rising Demand for Personalized Treatment
Matching therapies to individual disease activity, patient characteristics, and treatment preferences.
💉 Growth in High-Efficacy Biologics
Expanding the role of advanced therapies in managing active and aggressive disease.
💊 Increasing Adoption of Oral Therapies
Improving convenience and supporting long-term treatment adherence.
🌐 Expansion of Biosimilars and Generics
Creating opportunities to improve affordability and broaden access to established treatments.
🧪 Drug Repurposing and Progressive MS Research
Investigating existing medicines for potential neuroprotective and disease-modifying benefits, subject to clinical evidence and regulatory approval.

Market Segmentation

By Drug Class
• Interferon Beta
• Sphingosine 1-Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Monoclonal Antibodies
• Corticosteroids
• Adrenocorticotropic Hormone
• Others

By Disease Type
• Relapsing-Remitting MS (RRMS)
• Primary-Progressive MS (PPMS)
• Secondary-Progressive MS (SPMS)
• Progressive-Relapsing MS (PRMS)

By Route of Administration
• Parenteral
• Oral

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Why Invest in the Multiple Sclerosis Drugs Market Outlook 2036

✅ Projected growth from USD 22.3 Billion in 2025 to USD 39.7 Billion by 2036.
✅ Rising demand for long-term disease-modifying treatments.
✅ Continuous innovation in oral therapies and high-efficacy biologics.
✅ Growing opportunities in biosimilars and generic medicines.
✅ Increasing research into progressive MS and personalized treatment strategies.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=1130<ype=S

FAQs

1. What is the projected market size by 2036?
The global multiple sclerosis drugs market is projected to reach USD 39.7 Billion by 2036.

2. What is the CAGR of the market?
The market is expected to grow at a CAGR of 5.4% from 2026 to 2036.

3. What factors are driving market growth?
Key drivers include rising MS prevalence, improved diagnosis, increasing adoption of disease-modifying therapies, and advancements in oral medicines and biologics.

4. Which region dominates the market?
North America led the market in 2025, accounting for 39.7% of global revenue.

5. Which route of administration holds the largest share?
The parenteral segment dominated the market in 2025, with a 56.3% revenue share.

More Trending Reports by Transparency Market Research -

Monoclonal Antibodies Market: https://www.transparencymarketresearch.com/monoclonal-antibodies.html

Topical Antibiotics Market: https://www.transparencymarketresearch.com/topical-antibiotics-market.html

Gene Delivery System Market: https://www.transparencymarketresearch.com/gene-delivery-system-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com

This release was published on openPR.